Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide + RT for High-Risk Low-Grade Gliomas (RTOG 0424)
NCT00114140Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Jan 2005
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioma, sponsored by NRG Oncology. Primary endpoint: Overall Survival Rate at 3 years. Started Jan 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00114140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114140.